Biohit Oyj

Helsinki Stock Exchange BIOBV.HE

Biohit Oyj Net Income Margin for the year ending December 31, 2023: 14.16%

Biohit Oyj Net Income Margin is 14.16% for the year ending December 31, 2023, a 157.94% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Biohit Oyj Net Income Margin for the year ending December 31, 2022 was 5.49%, a 134.25% change year over year.
Biohit Oyj Net Income Margin for the year ending December 31, 2021 was -16.02%, a 65.54% change year over year.
Biohit Oyj Net Income Margin for the year ending December 31, 2020 was -46.50%, a -230.08% change year over year.
Biohit Oyj Net Income Margin for the year ending December 31, 2019 was -14.09%, a 34.72% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Helsinki Stock Exchange: BIOBV.HE

Biohit Oyj

CEO	Prof. Osmo Antero Suovaniemi M.D., Ph.D.
IPO Date	Jan. 3, 2000
Location	Finland
Headquarters	Laippatie 1
Employees	47
Sector	Healthcare
Industries Biotechnology Clinical Trials Dairy & Milk Medical Instruments Non-Alcoholic Beverages Organic Foods Pharmaceuticals Vaccines

Description

Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.

Key trends

Past 5 years